HBK Sorce Advisory LLC Grows Position in AbbVie Inc. $ABBV

HBK Sorce Advisory LLC boosted its position in shares of AbbVie Inc. (NYSE:ABBV) by 41.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 29,745 shares of the company’s stock after buying an additional 8,750 shares during the period. HBK Sorce Advisory LLC’s holdings in AbbVie were worth $6,878,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the company. Marshall & Sullivan Inc. WA purchased a new stake in AbbVie in the 2nd quarter valued at $25,000. Evolution Wealth Management Inc. acquired a new position in AbbVie in the second quarter valued at $26,000. TD Capital Management LLC raised its holdings in shares of AbbVie by 82.9% in the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after buying an additional 58 shares during the last quarter. Spurstone Advisory Services LLC acquired a new stake in shares of AbbVie during the second quarter worth about $28,000. Finally, Financial Gravity Companies Inc. purchased a new position in shares of AbbVie during the second quarter worth about $36,000. 70.23% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ABBV has been the subject of several analyst reports. Morgan Stanley upped their price objective on AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. Raymond James Financial set a $256.00 price target on AbbVie in a research note on Monday, November 3rd. UBS Group lifted their price objective on shares of AbbVie from $195.00 to $220.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Wells Fargo & Company boosted their price objective on shares of AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a research note on Friday, September 12th. Finally, BMO Capital Markets raised their target price on shares of AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a research note on Friday, September 12th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and an average target price of $245.84.

AbbVie Trading Up 0.4%

NYSE:ABBV opened at $227.82 on Tuesday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.60 and a current ratio of 0.72. The stock has a fifty day moving average price of $226.58 and a two-hundred day moving average price of $211.60. The stock has a market capitalization of $402.64 billion, a price-to-earnings ratio of 172.59, a PEG ratio of 1.29 and a beta of 0.36.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the prior year, the company posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, sell-side analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is 496.97%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.